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Background: Effective HIV protease inhibitors must combine potency towards 
wild-type and mutant variants of HIV with oral bioavailability such that drug levels 
in relevant tissues continuously exceed that required for inhibition of virus 
replication. Computer-aided design led to the discovery of cyclic urea inhibitors 
of the HIV protease. We set out to improve the physical properties and oral 
bioavailability of these compounds. 
Results: We have synthesized DMP 450 (his-methanesulfonic acid salt), a 
water-soluble cyclic urea compound and a potent inhibitor of HIV replication in 
cell culture that also inhibits variants of HIV with single amino acid substitutions 
in the protease. DMP 450 is highly selective for HIV protease, consistent with 
displacement of the retrovirus-specific structural water molecule. Single doses of 
IO mg kg-t DMP 450 result in plasma levels in man in excess of that required to 
inhibit wild-type and several mutant HIVs. A plasmid-based, in viva assay model 
suggests that maintenance of plasma levels of DMP 450 near the antiviral IC,, 
suppresses HIV protease activity in the animal. We did identify mutants that are 
resistant to DMP 450, however; multiple mutations within the protease gene 
caused a significant reduction in the antiviral response. 
Conclusions: DMP 450 is a significant advance within the cyclic urea class of 
HIV protease inhibitors due to its exceptional oral bioavailability. The data 
presented here suggest that an optimal cyclic urea will provide clinical benefit in 
treating AIDS if it combines favorable pharmacokinetics with potent activity 
against not only single mutants of HIV, but also multiply-mutant variants. 
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Introduction 
More is known about the structure [l-4] and essential 
functions [S-7] of the virally encoded protease of the 
human immunodeficiency virus (HIV) than perhaps any 
other single enzyme to date. The HIV protease has thus 
become an important target for the development of 
therapeutics for the treatment of AIDS [8,9]. Five 
peptide-like inhibitors of the HIV protease are currently 
in clinical trials [ 10-141; FDA approval has recently been 
granted to the inhibitors Saquinavir, Ritonavir and 
Indinavir [lo-121. The long-term clinical efficacy of these 
compounds is still under investigation, but the emergence 
of resistant viruses appears to be a potential limitation for 
all of them [15-181. Emergence of mutant HIV with 
decreased susceptibility to a protease inhibitor requires 
viral replication to continue in the presence of drug; it is 
therefore crucial to maintain the inhibitor at blood levels 
sufficient to inhibit the replication of both wild-type and 
mutant HIV Unfortunately, the peptide-like nature and 
size of many HIV protease inhibitors limit their oral 
bioavailability and half-life in man, making high blood 
levels difficult to achieve and sustain [19-211. Moreover, 
many peptide-like agents bind to plasma proteins, 
limiting the effective concentration of free drug available 
to interact with the intracellular target sites [Z?]. The 
challenges for designing a superior, or second-generation, 
inhibitor of the HIV protease are thus substantial. 
We previously described the use of structure-based drug 
design to produce a novel series of cyclic ureas, which are 
potent inhibitors of the HIV protease [23]. Cyclic ureas 
incorporate the hydrogen-bonding equivalents of an 
enzyme-bound water molecule into a low-molecular- 
weight, conformationally rigid, seven-membered ring 
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system. This structure permits optimal interaction of 
substituents with corresponding Sl, Sl’, S2 and S2’ 
pockets in the active site of the HIV-protease dimer. On 
the basis of favorable pharmacokinetics in the rat and the 
dog [24], the cyclic urea DMP 323 was selected for 
development proceeding to a Phase I clinical trial in 
non-HIV infected male volunteers. 
Although DMP 323 was a potent and selective inhibitor of 
the HIV protease [25], inhibited viral replication in a 
diverse array of laboratory isolates and cell types [26], and 
persistently inhibited viral polyprotein processing in 
chronically infected cells [27], its physicochemical prop- 
erties, in particular poor solubility in both aqueous and 
lipid media, limited development of an oral formulation 
that could reproducibly achieve satisfactory blood levels in 
humans. Our subsequent drug-discovery efforts focused on 
the identification of cyclic ureas with both improved 
physical properties and extended plasma half-life in animal 
model systems, while maintaining potency towards wild- 
type and mutant viruses. We report here the design, 
synthesis and characterization of DMP 450, a water soluble 
cyclic urea with significant oral bioavailability in animal 
species ranging from rat to man. Plasma levels (which take 
into account plasma-protein-bound drug) in man after 
single doses of 10 mg kg-’ are maintained above the 
concentration required to inhibit not only laboratory strains 
and clinical isolates of HIV, but also mutant viruses with 
single amino acid changes at residues corresponding to the 
Sl/Sl’ pocket of the protease. 
To examine the relative potency of DMP 450 in &o, we 
developed an assay system in which active protease 
expressed from recombinant plasmids injected into 
mouse skeletal muscle leads to loss of a heterologous 
plasmid-based reporter signal. DMP 450 is effective in 
this model system after intramuscular or oral dosing to 
the mice. Tissue culture studies in which HIV-infected 
cells are continuously exposed to DMP 450 indicate that 
multiply mutant variants of HIV can emerge, albeit 
slowly, and show considerable resistance to DMP 450. 
Three mutations appear to be required for significant 
(> 50-fold) attenuation of drug sensitivity. Taken 
together, these results suggest that cyclic ureas are a 
template that can provide clinically useful antiretroviral 
agents, and define an important and ambitious set of 
criteria for further optimization of cyclic urea inhibitors of 
the HIV protease. 
Results 
Synthesis of DMP 450 
We observed that symmetrical substitution of the urea 
nitrogens with meta- orpara-substituted benzyl groups led 
to moderate increases in potency relative to small alkyl 
substituents (F!Y.S.L. et al., unpublished data). If the 
benzylic substituent contained a hydrogen bond donor, as 
it does, for example, in DMP 323 (Fig. la), -lo-fold 
increases in both the enzymatic and antiviral potency 
resulted [23]. Since the unsatisfactory oral bioavailability 
in man of DMP 323 probably resulted from its poor 
solubility in both aqueous and lipid milieu, we sought to 
design benzylic-substituted cyclic ureas with acidic or 
basic functionalities. Basic groups enhance water 
solubility due to protonation. Attempts to introduce 
highly basic groups were uniformly unsuccessful, 
however, because in such structures a formal charge would 
need to have its associated water hydration shell stripped 
away before being forced into the solvent-sequestered 
SZ/SZ’ pocket. For example, the meta-aminomethylbenzyl 
analog has more than lOOO-fold weaker enzyme inhibitory 
activity than the isosteric meta-ethylbenzyl analog (data 
not shown). The weakly basic bis-meta-aminobenzyl 
derivative (DMP 450, compound 1, Fig. lb), however, 
showed enhanced affinity relative to its tolyl counterpart, 
perhaps because it binds to the enzyme in the neutral 
form, but can form an ionic interaction with Asp30 and 
Asp30’ (see below). The first pK, of the anilino residue 
was expected to be high enough to be protonated in the 
stomach and for formulation as salts of strong acids, but 
low enough to be neutral in the cytosol, and this turned 





Structures of (a) DMP 323 and (b) DMP 450. 
Research Paper Soluble cyclic urea inhibitor of HIV-1 protease Hodge et a/. 303 
Figure 2 
5 
(P = 2-methoxyethoxy) 
6 7 
8 (R = m-nitrobenzyl) 9 (R = m-nitrobenzyl) 
1 (R = m-aminobenzyl) 
Synthesis of DMP450. a: (COCI),, DMSO, CH,CI,, EtsN, -78 “C, 
84%. b: Zn”, CCI&THF),, CH,CI,, room temperature (rt), 55 % (pure 
RSSR isomer). c: DEA, MEM-Cl, reflux, 81 %. d: 1 atm H,, 10 o/, W/C, 
THF, rt. e: THF, 1,l ‘-carbonyl-diimidazole, rt, 76 Vo. f: NaH, m-nitrobenzyl 
bromide DMF, tt. g: MeOH, HCI, H,O, rt. h: EtOH, 1 N HCI, H,, W/C. 
For synthesis of laboratory quantities of DMP 450, we 
used vanadium-mediated pinacol coupling [28] of N-car- 
bobenzyloxy-d-phenylalaninal, as previously described 
[23,29-321 (Figure 2). The Materials and methods section 
provides full experimental procedures for the synthesis of 
cyclic ureas, some details of which have previously been 
published only in the patent literature [30,31]. The 
N-protected d-amino alcohol, required to set the stereo- 
chemistry of the ring substituents, was purchased in high 
optical purity (see Materials and methods). Oxidation, 
coupling, protection of the diol and deprotection of the 
amines, and cyclization with carbonyl diimidazole 
proceeded in acceptable yields. Alkylation with 3-nitro- 
benzyl bromide followed by reduction of the nitro groups 
and deprotection of the diol yielded pure DMP 450 in 
multigram quantities after chromatography or recrystal- 
lization. Modifications of this procedure for larger-scale 
preparation will be described elsewhere. 
Solubility 
The following amounts dissolved in 1 ml neutral water 
(range due to different recrystallization solvents): free base, 
0.004-0.005 mg; bis-HCl salt, 18-45 mg; bis-mesylate salt, 
>130 to >170 mg. 
Crystal structure of DMP 450 
Structural characterization of compounds 1, I*(MsOH)~ 
and l*(HCl), were carried out using standard X-ray 
crystallographic techniques (see Materials and methods). 
Two stereo views of the structure are shown in Figure 3. 
Normally, crystal packing contacts in cyclic ureas occur 
between the carbonyl and the hydroxyls (C.N.H. et al., 
unpublished data); in DMP 450, the protonated anilines 
are turned upwards to hydrogen-bond to crystallographic 
water, which in turn H-bonds to the hydroxyls. The 
conformation shown is similar to the conformation in 
complex with HIV protease, except that the aniline rings 
are rotated almost 90” (see Fig. 3). 
Inhibition of HIV protease by DMP 450 in vitro 
DMP 450 is a potent inhibitor of HIV-l protease as 
measured using peptide substrates or the HIV-l Gag 
polyprotein as a substrate (Table 1). The differences in 
potency values obtained in the two assays reflect 
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Figure 3 
Single crystal X-ray structure of DMP 450 
(his-hydrochloride salt). Two stereo views 
are shown, one with the O=C bond on the 2 
axis, and one with the CHOH-CHOH bond 
on the 2 axis. The counterions and water in 
the unit cell are not shown. In the complex 
with HIV protease, the aniline rings are 
rotated almost 90’ around the bond 
between the benzylic and aromatic carbon 
(arrows); otherwise the conformations are 
nearly identical (see later). 
differences in buffer composition, pH and concentration 
of protease used. DMP 450 is a competitive inhibitor of 
HIV-l protease, with rapid onset of inhibition (data not 
shown), as shown previously for the related cyclic urea 
DMP 323 [ZS]. As predicted for cyclic urea inhibitors, 
which incorporate a surrogate for the retrovirus-specific 
structural water molecule [23], DMP 450 inhibits mam- 
malian aspartic proteases only weakly (17 %  inhibition of 
pepsin at 1.2 m M  DMP 450, 3.5 %  inhibition of cathep- 
sin D and 54 5 33 %  inhibition of renin, both at 120 p,M), 
and failed to inhibit human pancreatic chymotrypsin and 
the chymotrypsin-like enzyme, neutrophil cathepsin G 
(0 %  inhibition at 120 ~.LM). The substrate specificities of 
the latter enzymes overlap that of HIV protease. 
Inhibition of HIV replication 
The measured concentrations required for 90 %  inhibition 
(IC,os) for four different types of antiviral assay and a 
variety of cell types and HIV isolates are shown in 
Table 1. DMP 450 is potent against laboratory strains of 
HIV-l and HIV-Z as well as primary, clinical isolates 
derived from AZTresistant patient samples. The concen- 
tration required to inhibit protease-mediated Gag poly- 
protein processing in persistently infected Molt-4 cells 
(0.24 pM) was similar to that required for antiviral activity 
as measured by reduction in the yield of infectious 
particles or in the level of viral RNA or ~24 Gag protein. 
Thus the antiviral effect can be fully explained by 
inhibition of the viral protease in the infected cells. The 
average value for IC,, against all HIV strains/cell types for 
all assays examined was 144 * 52 nM. Cell viability assays 
demonstrated that the concentration required to reduce 
viability by 50 %  (TC,,) for DMP 450 in MT-2 cells was 
greater than 80 ~.LM. In addition, DMP 450 shows a large 
dynamic range of dose dependent inhibition of virus 
replication, reducing the yield of infectious virus by more 
than three orders of magnitude at concentrations as low as 
0.5 PM (data not shown). 
To estimate the influence of plasma-protein binding on the 
ability of DMP 450 to inhibit replication, the two major 
components of human plasma, human serum albumin and 
o-l-acid glycoprotein, were added to the tissue-culture 
medium, and the IC,, was measured for production of viral 
RNA or infectious virus. The IC,, for wild-type virus was 
4.5-fold higher in the presence of these serum components 
when viral RNA was measured, and 8.4-fold higher in the 
presence of serum components when the yield of 
infectious progeny was measured by plaque assay. When 
lymphoid or monocytoid cell lines persistently infected 
with HIV-l or HIV-Z were exposed to DMP 450 for four 
days at a concentration of 8.2 p,M, progeny virion particles 
with morphology characteristic of immature particles, with 
uncondensed, partial cores, were observed (Fig. 4). 
Resistance profile 
Selected or recombinant viruses with amino acid substi- 
tutions corresponding to residues in the Sl, Sl’ and SZ, S2’ 
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Table 1 
Potency of DMP 450. 
Parameter 
Potencv 
Ki versus peptide substrate 
IC,, versus Gag substrate 
Mean f SD. 
0.28 f 0.09 nM 
76f54nM 
Virus Cells 
Potencv aaainst wild-type HIV 
HIV-1 (RF) MT-2 
HIV-1 (RF) MT-2 
HIV-1 (IIIB) MT-2 
HIV-1 (RF) Molt-4 
w-i (RF) PBMC 
HIV-I (RF) PBMC 








(virus ElDMP 323) MT-2 
sVal82Phe/lle84Val 















0.13 f 0.01 
0.15 f 0.08 
0.16 f 0.08 
0.24 
0.10 f 0.04 
0.12 
0.17 
0.18 f 0.06 
0.15 f 0.01 
0.04 
Yield 0.36 f 0.12 (2.8-fold incr.) Pharmacology profile 
Yield 1.28 f 0.25 (8.5-fold incr.) 
Yield 15.0 f0.94 (1 OO-fold incr.) 
ICC 0.12 f 0.03 
ICC 0.56 f 0.42 (4.7-fold incr.) 
ICC 0.88 f 0.41 (7-fold incr.) 
aThe yield of infectious particles was measured via plaque assay as 
described [26]. 
bViral RNA in infected cultures was measured via oligonucleotide 
capture/hybridization [521. 
%ral Gag polyproteins were measured by radioimmunoprecipitation 
assay in chronically infected cells [27]. 
dViral p24 antigen was measured by ELISA (DuPont NEN p24 
Assay Kit). 
*HIV isolate from AZT resistant patient peripheral blood mononuclear 
cells, IC,, for AZT > 4 PM). 
pockets of the HIV-protease dimer showed a lowered 
sensitivity to DMP 450, ranging from 2.8-fold (for a 
selected virus with a Va182Ala mutation) to 7-fold (for a 
recombinant virus with a Ile84Val mutation) increase in 
IC,, for mutant variants with a single amino acid sub- 
stitution. A loo-fold decrease in potency was, however, 
seen when recombinant virus selected kn vitro against the 
related cyclic urea DMP 323 [33] was used. This in vitro 
selected virus carries mutations corresponding to changes 
in amino acids 82 and 84, which occupy the Sl/Sl’ pockets 
and overlap with the SZ/SZ’ pockets in the protease dimer. 
To directly identify variants of HIV that may arise under 
selective pressure by DMP 450, two different isolates 
of HIV-1 were passaged in the presence of gradually 
increasing concentrations of DMP 450, as described 
previously for the in v&-o selection of DMP 323-resistant 
variants [33]. At selected passages, the sensitivity of virus 
to inhibition by DMP 450, and the sequence of the prote- 
ase gene of the virus present, was determined (Table 2). 
Donor E, an AZTresistant clinical isolate [33] that has a 
wild-type phenotype with respect to protease-inhibitor 
susceptibility, was passaged 29 times in increasing 
concentrations of DMP 4.50. Significant loss of sensitivity 
to DMP 450 (45-fold increase in IC,,) was associated with 
the presence of two to five mutations, including the 
Ile84Val mutation. Sequencing of virus with intermediate 
losses in sensitivity to DMP 450 inhibition suggests that 
mutation at position 46 is an early event, followed by 
mutation at position 84 and subsequently by mutation at 
positions 82,90 and 45 (Table 2). HIV H9466, which is also 
wild-type with respect to protease-inhibitor susceptibility 
[34], was passaged 29 times with increasing concentrations 
of DMP 450. Significant loss in virus sensitivity to 
DMP 450 inhibition was associated with the presence of 
four mutations, including a mutation of Ile84Val. 
Prior to conducting phase I studies in HIV seronegative, 
male volunteers, the effects of single and chronic dosing of 
DMP 450 in rodents and dogs was determined. No signifi- 
cant adverse effects were noted in these preliminary 
pharmacological assessments. Complete details will be 
published elsewhere. 
Pharmacokinetia of DMP 450 after oral and intravenous 
administration 
After IV administration of 10 mg kg’ of DMP 450 to ani- 
mals, plasma concentrations declined in a multiexponential 
fashion with terminal half-life values (tt,z) ranging from 0.8 
(rhesus monkeys) to 3.6 h (dogs) (Table 3). Apparent 
steady-state volume of distribution (Vss) was larger in all 
species than that expected for distribution to the total body 
water space (0.7 1 kg*) indicating extensive tissue 
distribution. After oral administration of a 10 (11 for human) 
mg kg* dose, the time after dosing when highest plasma 
concentrations were achieved (t,,,) varied among species 
ranging from 0.5 (rats) to 2.0 h (dogs) (Table 3). Under 
ketamine sedation in the chimpanzee (10 mg kg-l), tmax 
was delayed to 8 h postdose. The highest plasma concen- 
tration achieved after dosing (C,,) was greatest (11.19 p,M) 
in dogs, and lowest (1.53 p,M) in chimpanzees (Table 3). 
Bioavailability (the fraction of the dose absorbed into the 
bloodstream (F%)) ranged from 23.8 % in chimpanzee to 
79.3 % in the dog (Table 2). Plasma concentration versus 
time profiles for comparable perioral (PO) doses in all 
species are shown in Figure 5. 
Effect of oral DMP 450 administration on HIV protease in viva 
Direct injection of expression plasmids for luciferase and 
HIV protease into mouse quadriceps muscle resulted in 
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Figure 4 
Treatment of HIV-infected cells with 
DMP 450 causes production of immature 
virus particles. Electron micrographs of 
various cell lines chronically infected with HIV 
and treated for 4 days with DMP 450 are 
shown. Panels (a) and (b), Molt-4 cells 
infected with HIV-1 (RF); Panels (c) and (d), 
U937 cells infected with HIV-1 (RF); Panels 
(e) and (f), H9 cells infected with HIV- 
2(ROD). (a),(c),(e), untreated controls; 
(b),(d),(f), cells treated with 8.2 F M  DMP 
450. Bar = 200 nm. 
significantly decreased luciferase activity in muscle extracts 
compared to injection of luciferase plasmid alone (Table 4). 
We did not see this effect when the protease expression 
plasmid encoded HIV-protease containing a single, inactiv- 
ating amino acid substitution at the active site (AspZGly), 
indicating that the reduction in luciferase signal was due to 
HIV protease co-expression. When injected directly into 
the quadriceps muscle (10 p,g) or when administered orally 
at 100 mg kg*, DMP 450 provided complete protection of 
the luciferase signal. In contrast, DMP 323 caused some 
recovery of luciferase activity when injected intramuscularly, 
but failed to protect the luciferase signal at all when admin- 
istered twice daily (BID), even at 100 mg kg’ or PO at 200 
mg kg’ (B.K., @al., unpublished data). 
X-ray uystal structure of HIV-protease-DMP 450 complexes 
As shown in Figure 6, the bound DMP 450 links the active 
site aspartates to the flexible loops via a hydrogen bonding 
network without an intervening water molecule. The 
amine nitrogen of the m-aminobenzyl substituent is located 
within hydrogen bonding distance of the side chain of 
Asp30 and Asp30’ of the protease dimer. The benzyl groups 
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Table 2 
In vitro selection of DMP 450.resistant variants. 
Passage ‘%I Fold increase Amino acid 
b4 ml-’ 1 in IC,, sequence 
Donor E (initial) 0.065 1.0 Wild type 
Donor E Passage 18 0.665 10.2 Met46Leu 
Val82Valllle (mixture) 
lle84lle/Val (mixture) 





H9466 (initial) 0.095 1.0 Wild type 
H9466 Passage 12 0.917 9.7 AspGOGlu 
lle84Val 




vicinal to the diol oxygens occupy the Sl/Sl pockets as 
observed previously [‘23,35,36]. DMP 450 thus binds 
symmetrically to the HIV-protease dimer, in contrast to the 
asymmetric interactions reported for most [37-391, but not 
all [40] linear diol inhibitors of the enzyme. In addition to 
the steric fit of DMP 450 into the active site, the four strong 
hydrogen-bonding interactions (carbonyl, diol, anilines) 
provide a remarkable electrostatic complementarity that 
anchors and perhaps guides the inhibitor into place (Fig. 7). 
Discussion 
The recent studies of Ho et al. [41] and Shaw and 
colleagues [42] and their analysis by Coffin [43] have 
Table 3 
demonstrated that the HIV-seropositive individual is in a 
state of metastable equilibrium between HIV-mediated 
T-cell destruction linked to high levels of virus replication, 
and T-cell regeneration. An effective therapy must shift 
this balance in favor of cell repletion through significant 
reductions in the viral burden without concomitant en- 
richment and/or de nova generation of resistant mutant 
HIV if therapeutic benefit is to be sustained. Recent 
clinical trial results with the potent protease inhibitors 
Saquinavir [ 12,441, Indinavir [ 10,421, and Ritonavir 
[11,21,41,42], in which antiviral efficacy diminishes with 
treatment time, have shown that oral bioavailability and 
the ability to block the generation and/or outgrowth of 
resistant mutants of HIV are important in the clinical 
outcome of therapy as measured by plasma viral burden. 
The combined use of protease inhibitors and reverse 
transcriptase inhibitors is currently the most potent 
clinical option for relief of viral burden; long term efficacy 
and safety of such combinations is under investigation. We 
have focused on oral bioavailability and characterization of 
resistance profiles without sacrifice of sub-micromolar 
potency as key criteria in identifying a suitable clinical 
candidate within the cyclic urea series of protease 
inhibitors. This early focus on bioavailability together 
with the synthetic flexibility for introducing P2 and PZ’ 
substitutions onto the rigid, cyclic urea core structure have 
resulted in the design of DMP 450, a small, water soluble, 
HIV-protease inhibitor that is highly orally bioavailable. 
At sub-micromolar concentrations, DMP 450 is a potent 
inhibitor of the replications of laboratory strains and 
nucleoside-sensitive and resistant clinical isolates of HIV 
The suppression of virus replication - measured by 
quantitation of viral RNA, ~24 antigen, or production of 
infectious particles as assessed by plaque assay - 
correlated with the ability of DMP 450 to block processing 
Pharmacokinetics of DMP 450. 
Parameter Rat Dog Rhesus 
monkey 
Chimpanzeea Human 
IV dose (mg kg-‘) 10 10 10 10 
Cl (I h-1 kg-‘) 4.7 f 0.77 0.21 f 0.06 1.20 f 0.35 0.72 + 0.15 
Vss (I kg-‘) 4.52 + 0.42 1.35 + 0.48 1.37 f 0.32 1.57 + 0.39 
4/z 0-d 1.3 f 0.2 3.6 f 1 .O 0.8 + 0.1 2.6 + 1 .O 
PO dose (mg kg-‘) 10 10 10 10 lib 
Lx (PM) 2.25 f 0.72 11.19f1.33 1.60 + 1.67 1.53 f 0.92 6.49 +- 1.89 
t,,, 64 (range) 0.5 (0.25-0.75) 2.0 (1 .o-2.0) 1.5 (1 .o-3.0) 8.0 (4.0-8.0) 1.5 (1.0-l .5) 
F O/o 70.5 + 21.8 79.3 f 13.6 25.7 f 17.4 23.8 + 5.3 ND 
aChimpanzees were lightly sedated with 10 mg kg-’ ketamine prior to bAll subjects were given a fixed dose of 750 mg, average body weight 
dosing and before each specimen collection. was 67.9 kg. 






DMP 450 displays oral bioavailability in 
several species. The pharmacokinetics of 
DMP 450 after oral dosing is shown. Groups 
of animals.(n = 4-8) or healthy, HIV- 
seronegative human subjects (n = 8), were 
given DMP 450 in solution or as neat 
powder in capsules (see text). The dose was 
10 mg kg-l for all species except human, 
where the dose was 11 mg kg-‘. Plasma 
concentrations were determined by HPLC, 
and are expressed as JLM. 
,001 I I 
0 10 20 30 40 50 
Time after dosing (h) 
of the Gag polyprotein produced in chronically infected 
T-cells or macrophages and with the formation of im- 
mature particles with the characteristic non-condensed 
internal structure [45]. Previous studies with the related 
cyclic urea DMP 323 demonstrated that extended incu- 
bation of such immature particles after removal of the 
compound to a level below that required for significant 
inhibition of replication in vitro did not result in 
Table 4 
Activity of firefly luciferase in mouse muscle extracts. 
Plasmid injected Luciferase activitya 
(light units mg-l) 
No plasmid Cl00 
LUC plasmid alone 79 208 
LUC + HIV protease 9 504 
LUC + HIV protease Asp25Gly 73712 
LUC + HIV protease + DMP 323 (IM, 10 kg) 76 782 
LUC + HIV protease + DMP 450 (IM, 10 kg) 74 183 
LUC + HIV protease + DMP 323 (PO, 100 mg kg-‘) 11530 
LUC + HIV protease + DMP 450 (PO, 100 mg kg-l) 74 863 
aThe quadriceps muscles of Balb C mice were injected with the 
indicated plasmids either with or without concomitant dosing by the 
indicated route with cyclic ureas DMP 323 or DMP 450 as 
described in Materials and methods. After 48 h, luciferase activity 
was measured in quadriceps homogenates using firefly luciferin as 
substrate in the presence of ATP. Activity is expressed as light units 
per mg of muscle extract. 
maturation of the particles [‘27], suggesting that the timing 
of assembly events is critical for the formation of 
infectious, mature particles. Similar experiments with 
DMP 450 indicate that this cyclic urea also blocks 
polyprotein maturation such that maturation of latent 
particles does not occur after removal of the compound. 
DMP 450, like its predecessor DMP 323, showed a high 
degree of specificity for the HIV protease in comparison 
with other mammalian aspartic proteases and chymo- 
trypsin-like enzymes. This exquisite selectivity for HIV 
protease was predicted, since the cyclic urea framework 
incorporates the hydrogen-bonding equivalents of a struc- 
tural water molecule that is only present in retroviral 
proteases [l-4]. 
DMP 4.50 seems to have a resistance ‘profile’ qualitatively 
similar to that of DMP 323, consistent with the similarity 
of the X-ray structures of co-crystals of DMP 323 or 
DMP 4.50 with the HIV-protease dimer. The aromatic 
rings occupying the Sl/Sl’ pockets form hydrophobic 
interactions with the sidechains of Va182 and Ile84 that 
would be disrupted with mutations of these residues to 
the bulkier Phe or smaller Ala at position 82 or to the 
smaller Val at position 84. In contrast to DMP 323, where 
the para-hydroxymethylbenzyl groups on the urea 
nitrogens form hydrogen bonds with backbone amides 
between Asp29 and Asp30 and AspZ9’ and AspSO’, the 
me&-oriented amino group of DMP 450 allows for a 
(presumably) ionic hydrogen bond to the side chains of 
Asp29 and Asp29’. For the recombinant and selected 
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Figure 6 
DMP 450 binds symmetrically to the HIV-protease dimer. The X-ray 
crystal structure of DMP 450 bound to the active site of the HIV 
protease dimer is shown. All heavy atoms of the inhibitor are shown in 
ball and stick representation, and a selected portion of the protein 
backbone is shown as a ribbon; red for monomer 1 and green for 
monomer 2. The side chains of the active site aspartates, Asp 25 and 
Asp 25’, and of Asp 30 and Asp 30’ are also depicted in ball and stick 
representation. The urea oxygen of DMP 450 forms two long hydrogen 
bonds with flap residues lle50 and lle50’. The nitrogens of DMP 450 
are shown in blue, oxygens in red. Hydrogen bonds are depicted by 
dashed lines. 
viruses examined, single amino acid substitutions at posi- 
tion 82 or 84 result in a two- to seven-fold loss of sensi- 
tivity to inhibitor. These mutants can arise from wild type 
HIV by a single base pair change, and are thus likely to be 
present within the quasi species mixture that is now 
believed to characterize the HIV infected individual [43]. 
The double mutant Va182Phe/Ile84Val, which was iden- 
tified in tissue culture following prolonged growth of 
HIV in the presence of DMP 323, has a greater reduc- 
tion in sensitivity to DMP 4.50 than the product of the 
resistance observed for the single mutations alone. 
Efforts to understand the structural basis for this large 
loss of apparent binding affinity are currently in pro- 
gress. These two mutations do not appear to account for 
all of the changes in the DMP 323-selected virus, 
however. When the corresponding mutations were 
introduced into the HxB2 background, we could not 
recover infectious virus particles in the usual time 
required for mutant virus outgrowth, despite confirming 
proper plasmid construction and lipofection efficiency. 
This suggests that other mutational events, including 
changes outside the protease coding region, may have 
altered the relative replication competency of the 
double mutant during the selection experiments, such 
that it survives to become the majority population 
during the extended selection process. Such mutations 
might give rise to subtle conformational effects or 
encode outright changes in the processing-site sequence 
in the polyprotein substrate. Lamarre et al. [46] have 
recently presented evidence supporting the possibility 
that mutation of protease-processing sites is linked with 
the development of resistance-conferring mutations 
within the protease gene itself. 
A significant property of DMP 450 which is directly 
relevant to its potential for clinical efficacy is the 
substantial oral bioavailability observed in all species 
examined, including man. In single-dose pharmacokinetic 
studies, when delivered as a clear aqueous solution 
(pH -3) or as neat powder in gelatin capsules, plasma 
levels remained above the IC,, for wild-type HIV in all 
species for at least 3 h, and more than 10 h in dog, chimp, 
and human. Plasma levels remained above 1.3 p,M, which 
is the highest IC,, for known mutant HIVs containing 
single substitutions at position 82 or 84, for 4 h or more in 
Figure 7 
DMP 450 is electrostatically complementary to the HIV protease 
active site. The coordinates from the X-ray crystal structure were used 
to generate this graphical representation: hydrogens were added at 
pH 6.0 and partial and formal charges were assigned using Insight11 
(Biosym Technologies Inc., San Diego, CA). The catalytic aspartic 
acids were assigned a zero formal charge as determined by NMR 
spectroscopy of the DMP 323-HIV protease complex [35]. The 
electrostatic potential of the HIV protease in this model, with no 
inhibitor in the active site, was calculated using Delphi 1591 and a 
water-accessible surface area of the binding site within 4 A of DMP 
450 was color-coded by an electrostatic potential spectrum (blue = 
2 kcal mol-’ e-l; white = 0; red = - 2 kcal mol-l e-l). The inhibitor is 
color-coded by atom type to show the interaction of the oxygens and 
nitrogens with complementary charged regions of the enzyme active 
site. The Pl and P2’ benzylic groups are omitted for clarity. Note that 
the hydrogen atoms of the diol are not shown; these form an extensive 
hydrogen-bonded array with Asp25/25’ and Gly27/27’, and mediate 
the interaction between the diol oxygens and the proximal, negatively 
charged (red) regions of the catalytic triad. 
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human and dog at these single doses. When we adjust the 
IC,, values shown in Figure 5 for the 4-8-fold increase 
measured in the presence of human serum components, 
the plasma levels after acute dosing exceed even the 
adjusted IC,, for the Ile84Val mutant virus in the dog and 
in man for at least 2 h. 
In the clinical setting, it is the concentration of intra- 
cellular free, or ‘available’, compound concentration that 
will determine the level of inhibition observed and the 
resulting level of efficacy. Indeed, excessive plasma 
protein binding can lead to clinical failure, as recently 
observed with the HIV protease inhibitor SC-52151 [47]. 
DMP 450 binds to human plasma proteins, as determined 
by equilibrium dialysis using undiluted human plasma 
and 5 kg ml-’ of 14C-labeled compound, to the extent of 
90-93 %. This extent of binding is consistent with the 
4-B-fold upward-shift in IC,, measured in antiviral assays. 
The quantitative effect that this degree of protein binding, 
determined in a static system, will have on availability of 
compound for entry into cells and inhibition of protease 
within the HIV-infected individual remains to be 
determined. It was thus of interest to determine the 
potential for HIV-protease inhibition in an in vivo system 
used as a model of the complex and multi-compartment 
milieu encountered by an orally dosed pharmaceutical. 
Previous studies by Wolff et al. [48,49] have established 
that manual injection of plasmid DNA, encoding reporter 
genes, directly into striated muscles causes efficient syn- 
thesis of the reporter protein. Preliminary experiments in 
mammalian cell lines indicated that transient co-ex- 
pression of the HIV-l protease with a reporter protein 
such as firefly luciferase caused large reductions in the 
quantity of reporter activity as a result of protease activity 
in the cells; this effect could be blocked by treating the 
cells with protease inhibitors (B.K. et al., unpublished 
data). Based on the results of these transfection experi- 
ments, we have used the gene transfection technology of 
Wolff et al. to co-express HIV protease and luciferase in 
mouse muscle following injection of the corresponding 
plasmids. We then assessed the effect of orally or 
intramuscularly administered DMP 450. We also 
compared the relative potency of DMP 450 and 
DMP 323, which has a similar protein binding profile 
(88 %, [24]) but significantly lower bioavailability. 
Complete protection against protease-mediated loss of 
reporter signal was observed with local (intramuscular) 
injection of either cyclic urea, but only with DMP 450 
when the compounds were administered orally. 
Orally-delivered DMP 450 but not DMP 323 also delays 
HIV-protease mediated cataract development in a trans- 
genie mouse line in which the HIV-protease dimer is 
expressed from a transgene controlled by the lens 
o-crystalline promoter (Jonak, G.J., etal., (1993). EMBL 
Meeting on Mouse Molecular Genetics, Aug. 18-22, 1993, 
Abstract 258). Preliminary pharmacokinetic experiments 
in mice indicate that peak plasma levels of 7.2 FM and 4 h 
levels of 0.18 PM (total drug concentrations) are achieved 
following a 100 mg kg-’ PO dose of DMP 450. We have 
used a radioimmunoprecipitation (RIP) assay on extracts 
of cells in culture to determine the efficacy of the cyclic 
urea compounds in culture medium against the protease 
in an intracellular environment (Table 1 and [27]). If one 
assumes that the IC,, value obtained in these studies 
defines the plasma level of available drug that would be 
required to inhibit HIV replication in vzn/o, a level of 
-0.2 ELM would be required for either cyclic urea to yield 
90 %  inhibition. Our animal experiments indicate that 
measurable inhibition of protease activity within cells 
occurred with dosing regimens that resulted in total blood 
levels that exceeded the IC,,, determined by RIP in vitro, 
for at least part of the dosing interval. 
Taken together, the potency towards wild-type and mutant 
HIV, the pharmacokinetic profiles we have observed for 
single doses of DMP 450, and the desirable physico- 
chemical properties for an oral, solid-dosage form suggested 
the potential for clinical efficacy for this cyclic urea 
inhibitor of the HIV protease. In clinical trials to date with 
HIV-protease inhibitors, however, the initial efficacy as 
documented by viral load measurements is transient under 
several dosing regimes, due to the outgrowth of resistant 
virus under the selective pressure of drug therapy 
[21,41,42]. Whereas DMP 450 is effective against diverse 
wild-type isolates and against some mutants carrying single 
amino acid mutations within the protease, sensitivity of 
virus towards inhibition by DMP 450 was decreased in 
mutants harboring the Ile84Val mutation and was sub- 
stantially lowered in the presence of two or more muta- 
tions. Although viruses selected in vitro after exposure to 
the two related cyclic ureas DMP 323 [32] or DMP 450 
(Table 2) were not identical, the Ile84Val mutation was 
present in all of them. 
Rose et a/. [50] recently examined the influence of virus 
background on the vitality of mutant HIV variants; they 
propose that some mutant variants assembled and/or 
analyzed in vitro may never arise in v&o, depending on the 
background amino-acid sequences surrounding the muta- 
tions. This finding suggests that in vitro measurements of 
inhibitor potency towards mutant HIVs should be viewed 
with caution. But the fact that the Ile84Val mutation 
detected here was associated with loss of potency of 
DMP 450 in a variety of backgrounds, and was further 
aggravated by additional mutations, led us to anticipate 
that DMP 450 treatment would eventually lead to 
outgrowth of Ile84Val-containing viruses. Mutant viruses 
with changes at position 84 are also observed in vitro and in 
vtvo in association with exposure to the HIV-protease inhi- 
bitors Ritonavir and Indinavir [16,17]. Although DMP 450 
Research Paper Soluble cydic urea inhibitor of HIV-1 protease Hodge et al. 311 
is continuing in clinical trials with another sponsor, we are 
now focusing on identifying a third-generation cyclic urea 
inhibitor of the viral protease that will achieve blood levels 
of free drug sufficient to suppress replication HIV variants 
containing one or more mutations in addition to the 
Ile84Val substitution. Such an inhibitor could in principle 
be used as a single therapy or combined with any of the 
current clinical candidates or with inhibitors of other 
retroviral enzymes. 
Significance 
This study highlights the successful application of 
structural, chemical and biochemical data to the dis- 
covery of an improved HIV protease inhibitor, and 
continues the iterative process of identifying the 
properties necessary for an effective AIDS therapy. The 
introduction of water-solubilizing ionizable groups onto 
the already compact and pre-organized cyclic urea HIV- 
protease inhibitor resulted in a potent and selective 
antiviral agent with extremely favorable pharmaco- 
kinetic properties. Preclinical and clinical testing of 
DMP 450 and other protease inhibitors has established 
the importance of maintaining enzyme inhibition across 
a broad spectrum of potential and actual HIV protease 
mutant variants. Resistant strains have been identified 
that are associated with significant losses in drug 
potency for all of the antiviral agents currently in 
clinical trials; it is therefore uncertain whether these 
drugs can provide a sustained decrease in viral load that 
will lead to significantly improved immunocompetency. 
The DMP 450 structure, and cyclic ureas in general, 
provide a rigid, well-characterized physicochemical 
framework to continue the search for the optimal 
compound for use as a long-term treatment of AIDS. 
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Materials and methods 
Preparation of DMP 450 
All procedures were carried out under inert gas in oven-dried 
glassware unless otherwise indicated. 1 H-NMR spectra were obtained 
on VXR or Unity, 300 or 400 MHz instruments (Varian Instruments, 
Palo Alto) with tetramethylsilane as an internal reference standard. 
Melting points were determined on a Mettler SP61 apparatus and are 
uncorrected. Elemental analyses were performed by Quantitative 
Technologies, Inc., Bound Brook, NJ. High resolution mass spectra 
were carried out on a VG 70-VSE instrument with NH3 chemical 
ionization. Thin-layer and column chromatography were carried out on 
plates or silica gel from E. Merck, Darmstadt, Germany. Separation of 
optical isomers was performed using supercritical fluid 
chromatography with a Chiracel OD (Daicel Chemical Industries Ltd) 
and 20 % methanol-modified CO, mobile phase. Solvents and 
reagents were obtained from commercial vendors in the appropriate 
grade and used without further purification unless otherwise indicated. 
(R)-(phenylmethyl)-[2-hydroxy-1 -(phenylmethyl)ethyllcarbamate 
(compound 2) was purchased from Synthetech, Inc., Albany, OR; 
[a1250 = + 40.9 +I- 0.8 (C = 1 .Ol g per 100 ml EtOH). 
Synthesis of (R)-(phenylmethyi) (1 -formyl-2phenylethyl) 
carbamate (compound 3) 
A solution of 52 ml of oxalyl chloride (0.59 mol) in 500 ml dichloro- 
methane (CH,CI,) was cooled to -78 “C, and 57 ml anhydrous 
dimethylsulfoxide (0.81 mol) was added in 500 ml CH,CI, over 1 h 
while the temperature was maintained below -70 “C (caution: 
exothermic). Stirring was continued at -78 “C for 30 min and the 
alcohol 2 (125 g, 0.44 mol) was added in 800 ml CH,CI, over 1 h, 
again maintaining the temperature below -70 “C, followed by stirring 
for 30 min at -78 “C. Triethylamine (244 ml) was added in 300 ml 
CH,CI, over 0.5 h, followed by stirring for 2 h at -70 “C. After 800 ml 
of 20 o/, aqueous KHSO, was added, the reaction was allowed to 
warm to room temperature and 300 ml water was added. The aqueous 
phase was separated and washed with 400 ml CH,CI,, and the 
combined organic layers from two such runs were washed with 1 I of 
saturated aqueous NaHCO,, 1 I water and 1 I saturated aqueous 
NaCI, dried over MgSO, and concentrated to 700 ml. Hexane (2 I) was 
added, the mixture cooled in an ice bath for 1 h, and the solids were 
filtered and washed with cold hexane. After drying to constant weight 
at 40-50 “C, 209 g (84 o/o yield) of product was obtained, with a 
melting point (m.p.) of 82-83 “C; [a] 250 = +53.7 3~ 0.8 (C = I.049 per 
100 ml EtOH); NMR (300 MHz, CDCI,) 3.15 (d, J = 6 Hz, 2H); 4.5 (d, 
J = 12.6 Hz, 1 H); 5.1 (s, 2H); 5.35 (m, lH), 7.1-7.4 (m, IOH), 9.6 (br 
s, IH). The aldehyde, when pure, could be stored under inert gas 
without racemization or trimerization. Runs were pooled as necessary 
for the following step. 
Synthesis of [l R-(1 R*,2S*,3S*,4R*)]-bis(phenylmethyi) 2,3- 
dihydroxy-1,4-bis(phenylmethyl)-1,4-butanediylbis~carbamatel 
(compound 4) 
A four-necked reaction flask was charged with VCI,(THF), (467 g, 
1.25 mol) and 1 I CH,CI, in a dry box, removed from the dry box and 
fitted with a reflux condenser, a nitrogen bubbler, and a thermocouple. 
Zinc dust (Aldrich, 54 g, 0.83 mol, also weighed in the dry box) was 
added; the temperature rose to 40 “C. Aldehyde 3 (350 g, 1.2 mol) was 
added rapidly in 700 ml CH,CI,, the temperature rose to 40 “C, and the 
reaction was stirred overnight. A flask containing 6 I water and 500 ml 
concentrated HCI was warmed until the solution reached about 65 “C. 
The reaction mixture was added to the aqueous acid by addition funnel, 
and CH,CI, was collected in a cooled flask as it distilled. When addition 
was complete, the remaining material was allowed to cool to room 
temperature and the precipitate was collected and washed with water 
until colorless, then with 1.2 I ethanol, followed by 1.2 I hexane. The 
crude product was dried on the filter at 75 “C. Two of the above runs 
were combined and recrystallized by dissolving in hot tetrahydrofuran 
(THF), filtering, adding hexane and allowing to cool. A total of 374 g 
(55 o/o) of a white crystalline solid was recovered, m.p. 21 l-21 3 “C. 
HPLC analysis showed 97 o/, (1 R, 2S, 3S, 4R) isomer, 3 o/, (I R, 2R, 3R, 
4R) isomer. HRMS: calc’d, 569.2651; found, 569.2644. Recrystal- 
lization (CHClslhexane) gave analytically pure material: a white solid with 
m.p. 217-218 “C. Anal. calc’d. for C,,H,,N,O,: C, 71.81; H, 6.38; N, 
4.93; found: C, 71.70; H, 6.43; N, 4.90. 
Synthesis of [l R-(1 R*,2S*,3S*,4R*)]-bis(phenylmethyi) 2,3- 
bis[(2-methoxyethoxy)-methoxy]-1,4-bis(phenylmethy/)-1,4- 
butanediylbisfcarbamate] (compound 5) 
N,N-diisopropylethylamine (Aldrich; 1135 ml, 840 g, 6.5 mol) was 
added in one portion to a slurry of 600 g compound 4 (1 .I mol) in 5 I 
CH,CI, at room temperature followed by dropwise addition of 600 g 
2-methoxyethoxymethyl chloride (MEM-Cl, TCI America, Portland, OR; 
4.8 mol) over 1 h (caution: exothermic). The solution was heated at 
reflux for 12 h, followed by addition of 3 I ice water. The organic layer 
was separated and washed twice with 1.5 I water, then dried over 
magnesium sulfate. Solvent was removed to yield 890 g oil; this was 
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recrystallized with 1 -chlorobutane/hexane to yield 880 g (81 %) of a 
white solid, m.p. 52-54 “C. ‘H NMR (300 MHz, CDCI,): 2.8 (m, 4H, 
C&Ph); 3.38 (s, 8H, OCH,); 3.58 (m, 8H, OC&CH,O); 3.8 (m, 2H, 
CHOH); 4.2 (m,2H, CHNH); 4.8-5.2 (m, lOH, NH, PhCj&O, 
OCH,O); 7.25 (m, 2H, CsH,). M S  (ESI): 745( M+l, 23 46). HRMS: 
calc’d, 745.3700; found, 745.3715. Re-recrystallization gave a white 
solid, m.p. 57-58°C. Anal. calc’d for: C,,H,,N,O,,: C, 87.72; H, 
7.04; N, 3.78; found: C, 87.57; H, 7.08; N, 3.73 
Synthesis of [2R-(2R,3S,4S,5R)I-3,4-bi.s[(2- 
methoxyethoxy)methoxy]-1,6-diphenyl-2,5-hexanediamine 
(compound 6) and [4R-(4a,5a,6b,7b)I-hexahydro-5,6-bis[(2- 
methoxyethoxy)-methoxyl-4,7-bis~phenylmethyl)-2H-1,3- 
diazepin?-one (compound 7) 
THF (200 ml) and 20 g (28.8 mmol)  of compound 5 were stirred under 
1 atmosphere of hydrogen in the presence of 10 %  palladium on carbon 
(Aldrich) for 7 h or until thin-layer chromatography (TLC; 1O:l :lO ethyl 
acetate:ethanol:hexane, Rr = 0.05 for product) indicated that the 
reaction was complete. The suspension was filtered through a pad of 
diatomaceous earth and washed with 150 ml  THF. CDI (l,l’- 
carbonyldiimidazole, Aldrich; 5.5 g, 33.3 mmol)  was added directly to 
the solution in several portions as a solid followed by stirring at room 
temperature for 12 h or until the reaction was complete, as determined 
by TLC using the above solvent system @(,,,,t) = 0.28). The mixture 
was quenched with 150 ml  ice-cold 0.5N HCI and extracted twice with 
50 ml  diethyl ether; the combined organic phases were washed twice 
with 100 ml  water and dried over magnesium sulfate. Removal of 
solvent and silica-gel chromatography (1 :l hexane:ethyl acetate 
followed by 1O:l :lO acetate:ethanol:hexane) yielded 10.2 g (78 %  yield 
from compound 5) of a colorless oil. ‘H NMR (CDCI,): 2.90 (m, 4H, 
CH,Ph); 3.38 (s, 8H, OCH,); 3.4 (m, 8H, OCH,CH,O); 3.90 (t, 2H, 
OH); 4.10 (s, 2H, NH); 4.80 (q, 4H, OCH,CH,O); 7.3 (m, 1 OH, CsH,). 
Synthesis of [4R-(4a,5a,66,7b)]-hexahydro-5,6-bis(hydroxy)- 
1,3-bis[(3-nitrophenyl)methyl]-4,7-bis(phenylmethyl)-2H-1,3- 
diazepin?-one (compound 9) 
To a solution of 311 mg of MEM-protected cyclic urea 7 in 4 ml  of dry 
dimethylformamide was added 248 mg of 80 %  sodium hydride in 
mineral oil. The mixture was stirred for 15 min, and 804 mg of 
3-nitrobenzyl bromide was added. The mixture was stirred for 18 h, 
hydrolyzed with water and extracted with ether to give an oil that 
could be purified by preparative TLC on silica gel with 80:40 
hexane:ethyl acetate. A  major fraction (R, 0.14, 0.28 g, oil) 
was identified as [4R-(4a,5a,8b,7b)]-hexahydro-5,8-bis(2-methoxy- 
ethoxymethoxy)-l,3-bis([(3-nitro)phenyl]methyl)-2H-l ,3-diazepine-2- 
one by MS:  (M + H)+ = 773.3400; calc’d., 773.3398. For preparative 
purposes the protected bis-nitro compound was not isolated, but the 
2-methoxyethoxymethyl protective groups were removed directly by 
dissolving 173 mg of the above crude oil in 5 ml  of 4N HCl/dioxane. 
After 18 h the mixture was evaporated, and the crude product was 
purified by preparative TLC on silica1 gel with 95:5 dichlorometh- 
ane:methanol to give 0.11 g (R, 0.58) of crystalline compound 9, m.p. 
248.3 “C after recrystallization from ethanol. MS:  (m + H)+ = 597.2349; 
calc’d., 597.2349. 
Synthesis of [4R-(4a,5a,6b,7b)I-hexahydro-5,6-bis(hydroxy)- 
1,3-bis[(3-aminophenyl)methyl]-4,7-bis(phenylmethyl)-2H- 
1,3-diazepin-2-one (compound 1): free base, bis- 
hydrochloride, and bis-methanesulfonic acid salt (DMP 450) 
A mixture of 110 mg of compound 9,20 ml  ethanol, 2 ml  1 N HCI and 
40 mg of 10 %  PdlC was hydrogenated at atmospheric pressure for 
18 h. The product was purified by preparative TLC on silica gel with 
9O:lO dichloromethane:methanol to give 90 mg of the free base (R, 
0.41), m.p. 245.7 “C. MS:  (m + H)+ = 537.2854; calc’d., 537.2888. 
Bis-hydrochloride salt, m.p. 200 “C (dec), [a]25 = +107.28 (ethanol). 
Anal. calc’d. for C,,H,,N,0,.2HCI: C, 85.02; H, 8.28; N, 9.19, Cl, 
11.83.; found: C, 85.03; H, 8.48: N, 9.07. Cl, 11.38. Bis-methane- 
sulfonate salt (DMP450), m.p. 208.3”C (dec). Anal. calc’d. for 
C,,H,,N,0,.2CH,0,S.3H20: C, 53.89; H, 8.44; N, 7.18; 0, 24.52; 
S, 8.19; found: C, 53.28; H, 8.37; N, 7.05; 0, 24.07; S, 8.07. The 
solubility of the various salt forms was determined as described [51]. 
Single-crystal X-ray structure of DMP 450 
The bis-hydrochloride was crystallized by evaporation from etha- 
nol/water using a seed crystal from a 1 N HCI solution, to yield 
colorless monoclinic needles. Complete reports including data 
collection, atomic coordinates, thermal parameters, and interatomic 
distances and angles are available as supplementary material. 
Protease-inhibition assays 
Values for the inhibition constant, Ki, were determined with a 
fluorescent peptide substrate at pH 5.5 with 1 .O M  NaCI, as described 
previously [25]. A  polyprotein substrate corresponding to Gag pl7 
plus the first 78 amino acids of p24 was used to determine the 50 46 
inhibitory concentration (IC,,) for DMP 450 against HIV protease at 
pH 8.5, 0.15 M  NaCI. Inhibition of the aspartyl proteases human renin, 
porcine pepsin, bovine cathepsin D, and the chymotryptic enzymes 
human pancreatic chymotrypsin and human neutrophil cathep- 
sin G was measured as previously described [25] using DMP 450 
concentrations ranging from 12.5 F M  to 1.2 mM.  
Antiviral assays 
The ability of DMP 450 to inhibit HIV replication in tissue culture was 
assessed using four different assay systems. The yield of infectious 
virus produced in acute infections of MT-2 or HQ human T-lymphoid 
cells and in human peripheral blood mononuclear cells (PBMCs) was 
measured using a plaque assay as previously described [281. The 
antiviral activity of DMP 450 was also determined by measurement of 
viral RNA accumulation in HIV-1 (RF) acutely infected MT-2 cells as 
previously described [28,52]. The effect of DMP 450 on production of 
viral p24 antigen by HIV-infected PBMCs or MT-4 cells was measured 
using the AIDS Clinical Trials Group/Department of Defense PBMC 
consensus assay [53] for PBMCs,  or the method of Vacca et al. for 
MT-4 cells [lo]. The DuPont/NEN p24 ELISA kit was used for p24 
quantitation. To determine the influence of plasma protein binding on 
antiviral potency, human serum albumin (45 mg ml-‘) and a-l -acid 
glycoprotein (1 mg ml-‘) were added to tissue culture medium. To 
demonstrate that the antiviral activity of DMP 450 reflected inhibition of 
the HIV protease, the effect of DMP 450 on processing of the viral 
Gag polyprotein was measured by radioimmunoprecipitation of cellular 
and extracellular viral products from chronically infected Molt-4 human 
T-lymphoid cells or U937 human monocytoidlmacrophage cells as 
previously described 1271. In each case, the concentration of 
compound which reduced the measured parameter by 90% was 
designated the IC,,. The concentration of DMP450 required to 
reduce cell viability by 50 46 as determined using the tetrazolium dye 
MTT  (3-(4,5-dimethylthiaol-2-yi)-2,5-diphenyl tetrazolium bromide) was 
designated the TC,, [28]. 
Isolation of HIV-1 from clinical samples 
HIV-1 was isolated from patient PBMCs by cocultivation with phyto- 
hemagglutinin- and IL-2stimulated PBMCs from normal donors and 
resulting virus stocks were titrated using PBMCs as described 
previously [28,34]. 
Measurement of antiviral efficacy against mutant variants of HIV-l 
The ability of DMP 450 to inhibit the replication of drug-resistant 
variants of HIV-1 in human T-lymphoid cells or PBMCs was determined 
in two mutant virus assay systems. Mutant viruses, which were 
selected in vitro by continuous passage in the presence of a 
symmetrical diol protease inhibitor P9941 [541 or in the presence of 
the cyclic urea DMP 323 [33], were assessed for their susceptibility to 
DMP 450 in MT-2 cells using the yield reduction assay. The nucleotide 
sequence of the protease gene of these mutant viruses was determined. 
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Each virus is designated by the prefix s, to designate it as a selected 
virus, and the amino acid position of protease found to be altered. This 
is preceded and followed by the amino acid present in parental and 
variant virus, respectively, followed by the designation of the selecting 
HIV isolate and selecting agent. Thus sVal82Ala(RF/P9941) is a 
selected drug-resistant variant containing a single amino acid 
substitution of alanine for valine at position 82 of protease and was 
derived by tissue culture passage of HIV-1 (RF)-infected MT-2 cells 
against P9941 [54]. The double mutants sVal82Phe/Leu97Val(patient 
ElDMP 323) and sVal82Phellle84Val(RFlDMP 323) have been 
previously described [33]. In companion experiments, isogenic viruses 
with the noted protease-gene alterations in a constant HxB2 
background were reconstructed from plasmids that had undergone 
site-directed mutagenesis to insert specific base-pair changes leading 
to the desired amino-acid substitutions in the viral protease gene [55]. 
The reconstructed viruses were assessed for susceptibility towards 
DMP 450 using the recently adopted Inter-Company Consortium 
consensus assay, which measures production of viral p24 4 days after 
acute infection of MT-4 cells [lo]. The reconstructed recombinant 
viruses are named in the same manner as the selected viruses, with the 
r prefix to indicate their recombinant DNA origin. In vitro selection 
experiments were carried out essentially as described earlier for DMP 
323 [33]. Concentrations of DMP 450 were gradually increased over 
the course of 29 passages. For the HIV designated Donor E, passage 
1 contained 0.03 p,g ml-’ DMP 450; the concentration at passage 29 
was 3.0 pg ml-’ DMP 450. For HIV H9486, initial DMP 450 concen- 
tration was 0.05 ug ml-’ and was 3.0 pg ml-’ at passage 29. Deter- 
mination of IC,, by yield reduction, and preparation of samples for 
sequence determination were carried out as previously described [33]. 
Electron microscopy 
Molt-4 and U937 cells were infected with HIV-1 (RF) and chronically 
infected cells derived from extended passage in tissue culture. H9 
cells chronically infected with HIV-P(ROD) were produced in similar 
fashion. Cells were treated with 8.2 p,M DMP 450 for 4 days and cells 
prepared for electron microscopy as previously described (271. 
In vivo activity of DMP 450 in murine striated muscle 
Autologous plasmids that efficiently express the HIV protease or firefly 
luciferase genes were constructed using the human cytomegalovirus 
immediate-early promoter, an SV40 splice site and sequences to ensure 
polyadenylation. Standard methods were used for large scale plasmid 
preparation and CsCl purification [56]. Plasmids (in phosphate buffered 
saline pH 7.2) were injected into the quadriceps muscle of 30 day-old 
Balb C female mice under Avertin anesthesia. A maximum of 100 (~1 of 
solution was injected, containing 10 u,g luciferase plasmid with or 
without 30 kg of HIV protease expression plasmid. Animals were 
sacrificed after 48 h, the quadriceps muscles removed, weighed and 
extracted using mechanical homogenization in luciferase assay buffer as 
described [48,49]. Luciferase activity was determined using a Dynatech 
Model 1000 luminometer, measuring flash luminescence of 6 pM firefly 
luciferin (Sigma) containing 1 mM ATP. Mice were dosed with DMP 
450 at 10 p,g per quadriceps muscle or 100 mg kg-’ PO in water 8 h 
prior to the plasmid injection and BID for 2 days prior to sacrifice and 
preparation of homogenates for assay. A vehicle of 25:25:50 propylene 
glycol:polyethylene glycol400:water was used for DMP 323. 
X-ray crystallography of DMP 450-H/V protease 
inhibitor complexes 
Purified recombinant HIV protease mixed with a 1 O-fold molar excess 
of inhibitor was crystallized at pH 5.4 using conditions similar to those 
previously reported 1571. The crystal belongs to the space group p61 
a = b = 63.1 A, c = 83.4 A. Diffraction data were collected in 2” 
oscillation images exposed for 90 min using an R-axis imaging plate 
with an 82 mm crystal-to-detector distance. Intensities for 12478 
unique reflections representing 94 % of the possible data to 2.0 A 
resolution were obtained from 45866 independent measurements 
taken on 23 images (Rsym = 0.071). The initial R-factor was 0.27 using 
atomic coordinates from a model previously refined with other 
inhibitors of this series [23]. After crystallographic refinement by 
simulated annealing [58], the R-factor dropped to 0.23. Electron 
density maps calculated at this stage clearly revealed the bound 
conformation of the inhibitor. Geometric refinement parameters for the 
inhibitor were derived from its small molecule structure. The final R- 
factor is 0.21 for 8433 reflections to 2.0 A resolution for which 
F> 2a(F). Coordinates will be deposited in the Brookhaven Data Bank. 
Pharmacokinetics studies 
The pharmacokinetics of DMP 450 were investigated in the rat, dog, 
rhesus monkey, chimpanzee and HIV seronegative human volunteers. 
Dosing was IV or PO. The compound was administered PO in aqueous 
solution (rat, rhesus, chimpanzee) or as a dry powder in capsules (dog, 
human). Animals and human subjects were subjected to overnight fast. 
Dose is expressed as free base equivalents. Compound in plasma 
samples was isolated by solid-phase extraction, then quantified by 
HPLC-UV. The absolute oral bioavailability (F%) was determined by 
comparing the area under the plasma concentration versus time profiles 
for PO and IV doses, adjusting for differences in dose level. Full details 
will be published elsewhere ( L.S., M.G., et al., unpublished data). 
Supplementary material available 
Complete reports on the X-ray crystal structure of DMP 450, including 
data collection, atomic coordinates, thermal parameters and 
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